Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best mid-cap growth stocks to buy right now. On January 14, Bank of ...

Travere Therapeutics recently reported that the FDA has extended its review of the supplemental New Drug Application for ...

Travere Therapeutics FY25 sales surged on Filspari, but the FDA FSGS label decision was delayed to April. Click here to read ...

As of Tuesday, January 13, Travere Therapeutics, Inc.’s TVTX share price has dipped by 27.74%, which has investors ...

By Siddhi Mahatole and Sahil Pandey Jan 13 (Reuters) - The U.S. Food and Drug Administration has extended its review for the ...

Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Jan 13 (Reuters) - The U.S. Food and Drug Administration has extended its review for the expanded use of Travere Therapeutics ...

Lulu’s Fashion Lounge Holdings Inc (NASDAQ: LVLU) shares dipped 10.4% to $10.89 in pre-market trading. Lulu’s Fashion Lounge ...

U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025Company ...

Investing.com -- Travere Therapeutics (NASDAQ:TVTX) stock tumbled 33% Tuesday after the company revealed that the U.S. Food ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.